

Managing insomnia disorder in patients with neurological and psychiatric comorbidities

Lunch
available

Tuesday, 9 September | 12:45–14:15

Suntec Singapore Convention Centre, Singapore
Level 3, Nicoll 1

Chair: David Neubauer, United States Co-Chair: Lu Lin, China



- 12:45-13:05** ● **The impact of insomnia disorder for patients**
David Neubauer
United States
- 13:05-13:25** ● **New clinical data on daridorexant for managing insomnia disorder**
Atul Khullar
Canada
- 13:25-13:45** ● **Clinical experience managing insomnia disorder in patients with psychiatric comorbidities**
Laura Palagini
Italy
- 13:45-14:05** ● **Clinical experience managing insomnia disorder in patients with neurological comorbidities**
Claudio Liguori
Italy
- 14:05-14:15** ● **Panel discussion and Q&A**



Satellite Symposium at the 18th World Sleep Society Congress.
Supported by Idorsia Pharmaceuticals Ltd.



Managing insomnia disorder in patients with neurological and psychiatric comorbidities

Tuesday, 9 September | 12:45–14:15

Suntec Singapore Convention Centre, Singapore
Level 3, Nicoll 1


Dear Colleagues,

I am delighted to invite you to join us at a scientific satellite symposium addressing the latest developments in the treatment of insomnia disorder. Insomnia disorder is a complex, 24-hour disorder for patients which results in substantial impacts on daytime functioning and general wellbeing. We will therefore be addressing the **latest developments in the management of insomnia disorder in patients with neurological and psychiatric comorbidities.**

In this symposium, together with esteemed colleagues **Atul Khullar**, **Laura Palagini** and **Claudio Liguori**, we will explore the bi-directional relationship between sleep disturbances and neurological and psychiatric comorbidities in the context of the emerging role of hyperarousal. Following this, we will discuss new clinical data on the dual orexin receptor antagonist daridorexant as an important part of the evolving treatment landscape for insomnia disorder. A key feature of the symposium will be an in-depth examination of the practical considerations for managing insomnia disorder in patients with psychiatric and neurological comorbidities. The latest real-world data with daridorexant and relevant patient cases will be used to unpack key considerations when managing these patients with comorbidities.

We will wrap up with a Q&A session and panel discussion, providing attendees and experts the opportunity for dialogue and exchange. We look forward to a lively and stimulating discussion.

Best regards,



David Neubauer

Johns Hopkins School of Medicine,
Johns Hopkins Bayview Medical Center,
Baltimore, United States



September 5-10 **2025**
WORLD SLEEP
— Singapore —

idorsia
MED-GLO-DA-2500048